Virtual Library
Start Your Search
N. Xu
Author of
-
+
P3.01 - Advanced NSCLC (ID 621)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.01-025 - Treatment Outcomes of Advanced Lung Adenocarcinoma with Unknown EGFR Gene Status: A Retrospective Analysis of 140 Patients (ID 9036)
09:30 - 09:30 | Author(s): N. Xu
- Abstract
Background:
Limited data are available on treatment experience of advanced lung adenocarcinoma with unknown EGFR gene status (UN-EGFR-GS). We studied the demographic profile and treatment outcomes of advanced lung adenocarcinoma patients, which the EGFR gene status was unknown.
Method:
Retrospective study of patients with UN-EGFR-GS advanced lung adenocarcinoma over a 5-year period at a tertiary hospital in China. Patients diagnosed with stage IIIB or IV were included for analysis during 2010 and 2014.
Result:
In total, 140 patients were included, females and males constituted 48.6% (n=68) and 51.4% (n=72), respectively. The mean age was 58y. Among the 113 patients, 79 were non-smokers and 61 were smokers. Majority of patients had stage IV disease (90.0%), only 14 patients had stage IIIB disease. Most of the patients performance status (PS) score were 0 or 1 (n=128). Ninety-two patients were advanced stage when diagnosed and 48 patients were relapsed disease once received surgical resection. Nineteen patients received adjuvant chemotherapy, which were not relapsed in 6 months after finishing last cycle. In the140 patients, eighty-six had EGFR-TKIs ever, the rest were had chemotherapy only and never received EGFR-TKIs ever. The common regimens of first-line treatment were pemetrexed plus platinum (n=44), gemcitabine plus platinum (n=40), and paclitaxel plus platinum (n=18). Other drugs included docetaxel, novelbine. Twenty patients received EGFR-TKIs as first-line treatment. The commonest second-line treatment was oral EGFR-TKIs (n=47). Nineteen patients received EGFR-TKIs as third-line treatment and four received EGFR-TKIs as fourth-line treatment. At the end of follow-up (2016-7), 104 patients were dead and 36 patients were alive or lost follow up. The median survival of this whole cohort was 19.9m.Those who had a chance taken EGFR-TKIs lived longer than never; the median overall survival was 20.5 months and 16.4 months, respectively. EGFR-TKIs was associated with an improvement of overall survival, respectively in univariate analysis (p=0.027) and multvariate analysis (p=0.007). PS score was also associated with survival, respectively in univariate analysis (p＜0.01) and multvariate analysis (p＜0.01). The overall survival was not associated with sex (p=0.336), and smoking (p=0.414), TNM stage (p=0.565), age (p=0.100). The overall survival was also not associated with the chemotherapy drugs used in the first-line treatment.
Conclusion:
EGFR-TKIs have efficacy improved overall survival in patients with UN-EGFR-GS advanced lung adenocarcinoma, compared with conventional chemotherapy only. Oral EGFR-TKIs appear to be useful for this group of patients.
